A cure that exists but is inaccessible is inequality.
A medical breakthrough capable of curing sickle cell disease has arrived at a moment when Africa, home to 80 percent of the world's affected patients, can neither afford it nor access it. Uganda has taken a meaningful step by mandating newborn screening, yet the $2.2 million price of Casgevy gene therapy transforms a scientific triumph into a quiet testament to the world's unresolved hierarchies of care. The distance between what medicine can do and who medicine chooses to reach is not a technical problem — it is a moral one, written in the lives of children who will not survive to see a cure that already exists.
- Uganda's new mandatory newborn screening policy is a race against time — 80 percent of the 20,000 children born annually with sickle cell disease there die before age five, and early detection is their first real chance at survival.
- Casgevy, the CRISPR-based gene therapy hailed as a breakthrough in the US and UK, carries a $2.2 million price tag that renders it effectively nonexistent for the African patients who need it most.
- Nigeria registers 150,000 sickle cell births every year, yet patient advocates describe gene therapy as 'existing only on paper' — even the older bone marrow transplant option costs up to $200,000, far beyond most families' reach.
- Pharmaceutical manufacturers have stayed silent on pricing for low- and middle-income countries, and that silence is being heard across the continent as a definitive answer.
- A Ugandan research scientist is developing simplified manufacturing workflows that could bring gene therapy production into less-equipped local labs, but scaling that vision requires government investment that has not yet materialized.
- Advocates warn that celebrating a cure without confronting access is its own form of harm — creating a two-tiered world where the same disease means survival in wealthy nations and preventable death everywhere else.
Uganda this month made newborn sickle cell screening mandatory at all health facilities — a deliberate public health move aimed at catching the condition early in a country where roughly 80 percent of the 20,000 children born with the disease each year die before turning five. The policy is designed to change that arithmetic by identifying affected infants immediately and beginning treatment before complications take hold.
Yet the timing of this step forward collides with a stark reality. Casgevy, the CRISPR-based gene therapy approved by the FDA in late 2023, costs approximately $2.2 million per patient in the United States. Its manufacturer, Vertex, has disclosed no pricing for low- and middle-income countries. For advocates across Africa, that silence functions as an answer. Ayoola Olajide, president of a Nigerian sickle cell patient organization and himself living with the disease, said the therapy currently exists for African patients only on paper. "It gives hope but not much hope," he said. "You must be extremely wealthy to even think about it."
Africa carries roughly 80 percent of the global sickle cell burden. Nigeria alone sees 150,000 affected births each year. The disease — caused by a genetic mutation that deforms red blood cells into rigid, crescent shapes — brings severe pain, organ damage, and shortened lives. Casgevy addresses it at the molecular level, editing a patient's blood stem cells to restore healthy hemoglobin production. It works. The question is for whom.
The older alternative, bone marrow transplantation, costs between $50,000 and $200,000 — still far beyond most African families. Elisha Osati of the Tanzania Sickle Cell Disease Alliance noted that gene therapy's theoretical advantage — eliminating the need for a donor match, a particular challenge for African patients — disappears entirely when the cost is unreachable. "It's a hope that's almost impossible for our people," he said.
Lois Bayigga, a research scientist at Uganda's Joint Clinical Research Centre, is working on simplified manufacturing workflows that could allow gene therapy production in less-equipped local laboratories. She argues that local manufacturing would significantly reduce costs, and that emerging models already demonstrate the possibility. But she is equally clear about what must not be lost in the excitement over scientific progress. "All lives have equal value," she said. "If a cure exists but is inaccessible, that is inequality." Researchers and patient advocates agree: without African governments committing to invest in African-led solutions and local scientific infrastructure, the breakthrough will remain exactly what it is now — a cure for some people, in some places, while the regions bearing the heaviest burden continue to lose children to a disease that medicine already knows how to prevent.
Uganda this month began requiring all newborns delivered in health facilities to be screened for sickle cell disease at no cost—a straightforward public health measure designed to catch the condition early and prevent deaths among children who might otherwise go undiagnosed. The timing is deliberate. An estimated 20,000 Ugandan children are born with sickle cell disease each year, and without early intervention, roughly 80 percent of them die before turning five. The screening policy is meant to change that arithmetic by identifying affected infants immediately and starting treatment before complications take hold.
Yet as Uganda moves forward with detection, a celebrated medical breakthrough remains locked behind a price that makes it meaningless for nearly everyone in the region. Casgevy, a gene-editing therapy approved by the U.S. Food and Drug Administration in December 2023 and authorized by the UK's medicines regulator weeks earlier, costs approximately $2.2 million per patient in the United States. The manufacturer, Vertex, has not disclosed pricing for low- and middle-income countries, and Bluebird Bio, which produces a competing gene therapy called Lyfgenia, similarly declined to comment. For patients and advocates across Africa, the silence is answer enough.
The disease itself is straightforward in its cruelty. Sickle cell results from a mutation in the gene responsible for hemoglobin, the protein that ferries oxygen through red blood cells. The defect causes cells to become rigid and crescent-shaped, triggering severe pain, organ damage, and a shortened lifespan. Casgevy addresses this at the molecular level: doctors extract a patient's blood stem cells, use CRISPR gene-editing technology in a laboratory to reactivate healthy hemoglobin production, then reinfuse the edited cells after chemotherapy. Clinical trials showed the approach dramatically reduced severe pain episodes in most patients treated. It works. The problem is who gets to use it.
Africa carries roughly 80 percent of the global sickle cell disease burden. Nigeria alone sees 150,000 babies born with the condition each year—more than any other country on earth. Millions more people across the continent live with the disorder, many without consistent access to even basic medicines. Ayoola Olajide, president of the Ikorodu Sickle Cell Club in Nigeria and himself a person living with sickle cell disease, put it plainly: "For Africa, gene therapy treatment currently exists only on paper." He added that the price tag makes the therapy largely symbolic in a country where most families cannot afford basic medications. "It gives hope but not much hope," he said. "You must be extremely wealthy to even think about it and I know 99 per cent of the Nigerians cannot afford it so it's of no use to many."
For decades, the only established cure for sickle cell disease has been bone marrow transplantation, a procedure that requires a matched donor and carries its own risks. Nigeria has established three bone marrow transplant centers, but costs range from $50,000 to over $200,000—still far beyond reach for most families. Elisha Osati, chairman of the Tanzania Sickle Cell Disease Alliance, noted that gene therapy's theoretical advantage is that it eliminates the need for a donor match, a significant consideration for African patients who face lower donor match rates globally. But that advantage evaporates if the treatment itself is unaffordable. "Yes, gene therapy brings hope but it's a hope that's almost impossible for our people because of the cost," Osati said.
Lois Bayigga, a research scientist at Uganda's Joint Clinical Research Centre, explained that the price reflects both the scientific complexity and the infrastructure required. Most gene therapies rely on viral vectors and demand highly specialized manufacturing facilities that cost millions of dollars to build. Companies price treatments at extreme levels to recover those capital costs. Casgevy, while not dependent on viral delivery systems, still requires sophisticated laboratory processes and carefully controlled environments. But Bayigga is working on a simplified manufacturing workflow that could potentially function in settings like Uganda, using less complex lab infrastructure. "If viral vectors and gene therapy components were manufactured locally, pricing would drop significantly," she said. "There are emerging models that show gene therapy work can be done in simpler labs."
Advocates stress that while gene therapy generates excitement in wealthy countries, African governments must prioritize prevention, screening, and accessible treatment first. Uganda's mandatory newborn screening policy reflects that strategy—expanding early diagnosis and ensuring immediate initiation of lifelong medication where needed. But Bayigga warned against celebrating cures without addressing access. "All lives have equal value," she said. "If a cure exists but is inaccessible, that is inequality. It creates hope for some, but pain for others who know they will never access it." The path forward, according to researchers and patient advocates, requires African governments to become the biggest investors in African-led solutions, training local scientists and building the infrastructure to manufacture these therapies domestically. Without that commitment, the breakthrough will remain what it is now: a cure that exists for some people, in some places, while children in the regions bearing the heaviest disease burden continue to die from a condition that medicine can now prevent.
Citas Notables
For Africa, gene therapy treatment currently exists only on paper.— Ayoola Olajide, president of Ikorodu Sickle Cell Club, Nigeria
If a cure exists but is inaccessible, that is inequality. It creates hope for some, but pain for others who know they will never access it.— Lois Bayigga, research scientist, Uganda's Joint Clinical Research Centre
La Conversación del Hearth Otra perspectiva de la historia
Why does Uganda's screening policy matter if the actual cure is unaffordable?
Because early detection changes what's possible with existing treatments. If you catch sickle cell at birth, you can start pain management, prevent infections, monitor for complications. You don't cure it, but you keep children alive long enough to reach adulthood. Without screening, many die before anyone even knows what's wrong.
So the screening buys time.
Exactly. It buys time and it buys dignity—knowing what you're dealing with instead of watching your child suffer without understanding why. But yes, it also buys time in another sense: time for the world to figure out how to make gene therapy affordable.
Is the $2.2 million price actually justified by the science?
That's the question everyone's asking. The science is genuinely complex and the manufacturing facilities are expensive. But researchers like Bayigga think the price also reflects a business model built for wealthy markets. If you manufacture locally, use simpler lab processes, you could drop the cost substantially. The technology itself isn't the barrier—it's the infrastructure and the profit margins.
Why won't Vertex or Bluebird Bio say what they'd charge in Africa?
Silence is its own answer. If they had a plan to make it accessible, they'd say so. The fact that they didn't respond suggests they either haven't thought about it or they know the answer would be uncomfortable. Either way, it tells you where the priority lies.
What does Olajide mean when he says gene therapy exists "only on paper" in Africa?
He means it's real, it works, it's approved—but it might as well be fiction for anyone in Nigeria or Uganda. It's a cure that exists in medical journals and press releases, not in hospitals where his patients can actually reach it. That's the cruelty of it: the solution exists, but the people who need it most can't have it.
Is there any realistic path to making this affordable?
Yes, but it requires governments to act like Bayigga said—to invest in local manufacturing, to train scientists, to build the infrastructure themselves instead of waiting for companies to do it. It's not impossible. It's just expensive upfront and requires political will that hasn't materialized yet.